- Life Expectancy
- Risk Factors
- Signs & Symptoms
- Related Resources
Spinal muscular atrophy (SMA) is a debilitating disease that can be classified as a disability if symptoms are severe enough to cause significant impairments. SMA is hereditary and progressive, affecting both the central and peripheral nervous systems as well as voluntary muscle function.
The disease destroys motor neurons in the brainstem and spinal cord.
- Motor neurons are nerve cells responsible for skeletal muscle function, which include muscles in our arms, legs, chest, face, throat, and tongue.
- Destruction of motor neurons disrupts the signals from the neurons to the muscles, and over time, the muscles gradually weaken and waste away (atrophy).
What is the life expectancy of someone with spinal muscular atrophy?
Life expectancy depends on the severity of the disease:
- Type 0: Babies with SMA type 0 have fragile respiratory muscles and many also have congenital heart defects. Type 0 babies rarely survive beyond 6 months.
- Type 1: Most children with SMA type 1 do not survive beyond the age of 2 because of respiratory issues. New treatments, however, have helped prolong the life of children with SMA1 and enabled them to sit and even walk.
- Type 2: Most children with SMA type 2 survive into adolescence or young adulthood. Current disease-modifying treatments help improve muscle function and quality of life in these children.
- Type 3: With appropriate care and treatment, most patients with SMA type 3 have an average life span. Treatment can improve motor function and slow down the progression of the disease.
- Type 4: Life expectancy is normal in people with SMA type 4 and most remain mobile and active throughout their lives. Treatment can slow down disease progression and prevent complications.
Who is affected by the disease?
The earlier in life the disease develops, the more severe it is:
- Approximately 60% of children with spinal muscular atrophy are born with the condition or develop it within the first 6 months of life. Children who develop spinal muscular atrophy after 6 months of age may be able to sit, depending on the severity, but most cannot walk.
- Children who develop the disease in their teens may initially have muscle weakness, but some eventually lose the ability to stand or walk.
- Adult-onset of spinal muscular atrophy is rare and accounts for only about 5% of cases. People who develop spinal muscular atrophy as adults usually have muscle weakness, but most can manage the condition with treatment and exercise and remain mobile throughout their lives.
What are the signs and symptoms of spinal muscular atrophy?
Symptoms vary depending on the type and severity of the disease. Some people are never able to sit, stand or walk, and some lose these abilities gradually due to increasing muscle loss with age.
There are five types of spinal muscular atrophy:
Type 0 (SMA0)
Type 0 SMA is the rarest and most severe form, developing in babies in the womb. Fetal movement decreases and the baby is born with congenital heart defects, breathing difficulty, facial paralysis (facial diplegia), low muscle tone (hypotonia), and muscle weakness.
Type 1 (SMA1)
Also known as Werdnig-Hoffman disease, type 1 is a severe form of SMA that presents at birth or develops before a baby is six months old.
- A child with type 1 SMA cannot sit up without support, and has trouble breathing, sucking, and swallowing.
Type 2 (SMA2)
Type 2 accounts for about 20% of SMA cases and develops in children between 6-18 months of age. Also known as intermediate SMA or Dubowitz disease, type 2 SMA usually affects the legs more than the arms.
- An affected child may be able to sit without support but may not be able to stand or walk, and some may have respiratory difficulties, weird faces, and microcephaly.
Type 3 (SMA3)
Also known as juvenile-onset SMA or Kugelberg-Welander disease, type 3 SMA is a milder disease that develops after 18 months of age and makes up 30% of all SMA cases.
- Children with type 3 SMA can stand and walk without support but have difficulty running, climbing stairs, and getting up from a chair. Most patients develop foot deformities, sideways spine curvature (scoliosis), and respiratory issues, eventually becoming wheelchair-dependent.
Type 4 (SMA4)
Type 4 SMA is a mild form that develops in adulthood, usually after age 30. It accounts for less than 5% of all SMA cases.
- Symptoms may include muscle weakness, twitching, and breathing difficulties. Most people with type 4 SMA can maintain mobility with appropriate treatment and exercise.
What causes spinal muscular atrophy?
SMA is caused by inherited genetic defects. The most common form of the disease is caused by mutations in both copies of a gene known as survival motor neuron 1 (SMN1) on chromosome 5. The SMN1 gene encodes SMN protein, which maintains motor neuron health and normal functioning.
In 95%-98% of SMA cases, both copies of the SMN1 gene are missing. About 2.5% have mutations that cause low production of SMN protein. A low level of SMN protein destroys motor neurons; as a result, the skeletal muscles weaken and waste away. This can lead to disability and even death in severe cases.
Many people with defective SMN1 usually have extra copies of the SMN2 gene, which mainly produces shorter-length SMN proteins. But it also makes a small amount (10%-15%) of functional full-length SMN protein. Some people may have even up to 8 copies of the SMN2 gene which increases the level of functional SMN protein and results in milder forms of the disease.
If someone has a mutation in one copy of an SMN1 gene, they may not be affected by the disease but can be a carrier and pass it on to their child. If both parents are carriers of SMN1, a child has about a 25% chance of developing SMA.
Less common forms of SMA are caused by mutations in other genes which include:
- VAPB gene on chromosome 20
- DYNC1H1 gene on chromosome 14
- BICD2 gene on chromosome 9
- UBA1 gene on the X chromosome
Except for the UBA1 gene mutation on sex chromosome X, all others are autosomal recessive diseases. The 22 pairs of numbered chromosomes in the human cell are known as autosomes, except chromosomes X and Y which are the 23rd pair and determine gender.
We inherit a set of 23 chromosomes from each parent, with one copy of each gene on the 22 chromosomes, along with an X from our mother and an X or Y from our father. Autosomal recessive diseases occur when both copies of the same gene are missing or defective.
- FDA's Food Safety Program Needs a Revamp: Panel
- Drug Choice Might Matter for Patients With Macular Degeneration
- Record Number of Fatal Drug ODs for Pregnant, Postpartum Women
- Minor Facial Scars Don't Affect Others' First Impressions, Study Finds
- U.S. States With Tighter Access to Welfare Payments Have More Kids in Foster Care
- More Health News »
How is spinal muscular atrophy diagnosed?
Diagnosis begins with a classification of SMA. Along with a clinical assessment of symptoms, diagnostic tests that can help confirm the diagnosis include:
- Genetic testing with a blood sample, which is the most accurate method.
- Blood test for an enzyme called creatine kinase (CK) which leaks out of muscles that break down. CK values are usually average in SMA1, but are slightly elevated in SMA2 and SMA3 and can be confused with other muscle-wasting diseases.
- Electromyogram, is a test that uses low electric pulses to measure electrical activity in the muscles.
- Nerve conduction study, which assesses the speed with which signals are transmitted through motor neurons.
- Muscle biopsy, in which muscle tissue sample is analyzed under a microscope.
Can spinal muscular atrophy be treated?
While SMA can be treated to alleviate symptoms, slow down the progression of the disease, and prolong and improve quality of life, the condition is not curable.
- Treatment is highly effective in managing symptoms in SMA4 patients; most are mobile throughout their lives.
- Early diagnosis (before permanent motor neuron damage occurs) and appropriate treatment can improve outcomes for patients with SMA2 and SMA3.
- New gene therapies and disease-modifying medications targeting the SMN1 and SMN2 genes, which increase the production of SMN protein and reduce motor neuron loss, have helped improve prognosis.
In May 2015, the U.S. Department of Health and Human Services (HHS) approved the addition of spinal muscular atrophy to the Recommended Uniform Screening Panel (RUSP) for newborns. This may help in early diagnosis and prompt treatment, which can be life-saving, especially with the research of more effective medications.
What is the treatment for spinal muscular atrophy?
Treatment for spinal muscular atrophy depends on the severity of the disease and includes disease-modifying medications and treatment for symptoms and complications. Patients also have the option to enroll in clinical trials for new therapies.
The FDA has approved three disease-modifying medications to treat SMA caused by a missing or mutated SMN1 gene:
- Nusinersen sodium (Spinraza): Nusinersen is administered with an injection into the cerebrospinal fluid in the spinal canal. Nusinersen modifies the SMN2 gene to increase its production of functional SMN protein. Nusinersen is approved for use in children and adults.
- Onasemnogene abeparvovec-xioi (Zolgensma): Zolgensma is a gene replacement therapy administered with intravenous infusion. A non-infectious virus delivers a fully functional SMN1 gene into the motor neurons, which increases the production of SMN protein. Zolgensma is a one-time therapy approved for children below 2 years of age.
- Risdiplam (Evrysdi): Risdiplam is an oral solution that modifies the SMN2 gene to make it produce a more functional SMN protein. Risdiplam is approved for children over 2 months of age and is a life-long treatment.
Symptom and complication therapies
Treatment to relieve symptoms and alleviate complications vary depending on the patient’s condition. Therapies may include:
- Breathing support and devices to remove respiratory secretions (if the patient has respiratory muscle weakness)
- Feeding tubes for weakness in the chewing and swallowing muscles
- Physical and occupational therapies
- Supportive aids such as back braces, leg braces, walkers, or wheelchairs
- Surgery to treat hip dislocations, fractures, or scoliosis
Health Solutions From Our Sponsors
Top Is Spinal Muscular Atrophy a Disability? Related Articles
Back Pain: Common Spine ProblemsThat stack of little bones along the center of your back has a key role to support and control your body. What happens when something's not right with your spine?
Can I Get Disability For HSThe Social Security Administration (SSA) recognizes hidradenitis suppurativa (HS) as a potentially disabling disease. For HS to be considered a disability, your symptoms must be severe enough to keep you out of work for 12 months or longer.
Can You Get Disability for Ankylosing Spondylitis?A patient is eligible for disability benefits for ankylosing spondylitis (AS) if the condition is considered severe and serious. Below are the criteria to get disability benefits for AS
Does NMO Qualify for Disability?Neuromyelitis optica or NMO qualifies for severe disability because it affects the central nervous system, causing blindness and paralysis.
Genetic Diseases (Disorder Definition, Types, and Examples)The definition of a genetic disease is a disorder or condition caused by abnormalities in a person's genome. Some types of genetic inheritance include single inheritance, including cystic fibrosis, sickle cell anemia, Marfan syndrome, and hemochromatosis. Other types of genetic diseases include multifactorial inheritance. Still other types of genetic diseases include chromosome abnormalities (for example, Turner syndrome, and Klinefelter syndrome), and mitochondrial inheritance (for example, epilepsy and dementia).
How Common Is Spinal Muscular Atrophy?Spinal muscular atrophy (SMA) is a hereditary (running in families) disorder that progressively destroys the motor nerve cells (neurons) leading to muscle weakness and wasting (atrophy).
How Do You Diagnose Spinal Muscular Atrophy?Spinal muscular atrophy (SMA) is a genetic condition that results in weakness and wasting of muscles in infants. For diagnosing spinal muscular atrophy (SMA), certain tests are carried out to check if your child has this condition.
Is CLL a Disability?Leukemia is the cancer of the white blood cells of the bone marrow (spongy part of long bones). Patients with leukemia have an overproduction of a type of blood white cell in the body. In chronic lymphocytic leukemia (CLL), the bone marrow produces too many immature lymphocytes (a type of white cells).
Is Crohn’s Disease a Disability?Crohn’s disease can be debilitating, negatively affecting the digestive system and hampering the ability to eat or have normal bowel movements. It therefore qualifies as a disability under the ADA.
Is Spinal Muscular Atrophy a Motor Neuron Disease?Spinal muscular atrophy (SMA) is a type of genetic condition that affects the nerve cells regulating the muscles that help move around (motor neurons), resulting in weakness and wasting (atrophy) of these muscles.
Is Spinal Muscular Atrophy Treatable?Spinal muscular atrophy (SMA) is a type of motor neuron disease that is hereditary. Treatment of spinal muscular atrophy includes prescription medication, suctioning mucus from the throat, external oxygen support and breathing exercises.
Spinal Muscular Atrophy (SMA)
Spinal muscular atrophy (SMA) is an inherited (genetic) disease that attacks motor neurons (nerve cells) in the spinal cord. As the nerve cells die, muscle cells weaken and cause signs and symptoms that affect head and neck control, walking, crawling, breathing, and swallowing.There are numerous types of spinal muscle atrophy. Treatments for spinal muscle atrophy are directed at managing symptoms of the disease. There is no cure for spinal muscle atrophy, and some types cause death.